Treatment Patterns and Use of Immune Checkpoint Inhibitors Among Patients with Metastatic Bladder Cancer in a Dutch Nationwide Cohort.
Since 2017, two immune checkpoint inhibitors (ICIs) have become the standard of care for the treatment of metastatic urothelial carcinoma in Europe: pembrolizumab as second-line therapy and avelumab as maintenance therapy. Our aim was to describe the use of ICIs as first and later lines of treatment in patients with metastatic bladder cancer (mBC) in the Netherlands. We identified all patients diagnosed with primary mBC between 2018 and 2021 in the Netherlands from the Netherlands Cancer Registry (NCR). NCR data were supplemented with data from the Dutch nationwide Prospective Bladder Cancer I... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2024 |
Verlag/Hrsg.: |
Elsevier
|
Schlagwörter: | 610 Medicine & health |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-27449145 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://boris.unibe.ch/191598/1/1-s2.0-S2666168323025302-main.pdf |